Michelle Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michelle Luo has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Aaron J. Weiss
Department of Cardiovascular and Thoracic Surgery, Sandra Atlas Bass Heart Hospital at North Shore University Hospital, Northwell Health, Manhasset, New York
2 shared publications - Adam C. Winters
Recanati/Miller Transplantation Institute, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publications - Andres J. Yarur
Cedars Sinai Medical Center, F. Widjaja Inflammatory Bowel Disease Institute , Los Angeles, CA
2 shared publications - Arun Swaminath
Division of Gastroenterology, Lenox Hill Hospital , New York, NY 10025
2 shared publications B E Sands
Icahn School of Medicine at Mount Sinai, New York, USA
2 shared publications- Bo Shen
Center for Inflammatory Bowel Disease and the Global Center for Integrated Colorectal Surgery and IBD Interventional Endoscopy, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, New York
2 shared publications
Latest Publications
- Open Access
- 26 April 2024
- Published by Elsevier in Extracellular Vesicle
- Vol. 3
The EV antibody database: An interactive database of curated antibodies for extracellular vesicle and nanoparticle research
- 26 April 2024
- Published by Elsevier in Extracellular Vesicle
- Vol. 3
Open AccessThe EV antibody database: An interactive database of curated antibodies for extracellular vesicle and nanoparticle research
- 1 February 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (5) , 444-455
Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration
Transglutaminase factor XIII (FXIII) is essential for hemostasis, wound healing, and pregnancy maintenance. Plasma FXIII is composed of A and B subunit dimers synthesized in cells of hematopoietic origin and hepatocytes, respectively. The subunits associate tightly in circulation as FXIII-A2B2. FXIII-B2 stabilizes the (pro)active site-containing FXIII-A subunits. Interestingly, people with genetic FXIII-A deficiency have decreased FXIII-B2, and therapeutic infusion of recombinant FXIII-A2 (rFXIII-A2) increases FXIII-B2, suggesting FXIII-A regulates FXIII-B secretion, production, and/or clearance. We analyzed humans and mice with genetic FXIII-A deficiency and developed a mouse model of rFXIII-A2 infusion to define mechanisms mediating plasma FXIII-B levels. Like humans with FXIII-A deficiency, mice with genetic FXIII-A deficiency had reduced circulating FXIII-B2, and infusion of FXIII-A2 increased FXIII-B2. FXIII-A-deficient mice had normal hepatic function and did not store FXIII-B in liver, indicating FXIII-A does not mediate FXIII-B secretion. Transcriptional analysis and polysome profiling indicated similar F13b levels and ribosome occupancy in FXIII-A-sufficient and -deficient mice and in FXIII-A-deficient mice infused with rFXIII-A2, indicating FXIII-A does not induce de novo FXIII-B synthesis. Unexpectedly, pharmacokinetic/pharmacodynamic modeling of FXIII-B antigen after rFXIII-A2 infusion in humans and mice suggested FXIII-A2 slows FXIII-B2 loss from plasma. Accordingly, comparison of free FXIII-B2 vs FXIII-A2-complexed FXIII-B2 (FXIII-A2B2) infused into mice revealed faster clearance of free FXIII-B2. These data show FXIII-A2 prevents FXIII-B2 loss from circulation and establish the mechanism underlying FXIII-B2 behavior in FXIII-A deficiency and during rFXIII-A2 therapy. Our findings reveal a unique, reciprocal relationship between independently synthesized subunits that mediate an essential hemostatic protein in circulation. This trial was registered at www.ClinicalTrials.com as #NCT00978380.
- 1 February 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (5) , 444-455
Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration
Transglutaminase factor XIII (FXIII) is essential for hemostasis, wound healing, and pregnancy maintenance. Plasma FXIII is composed of A and B subunit dimers synthesized in cells of hematopoietic origin and hepatocytes, respectively. The subunits associate tightly in circulation as FXIII-A2B2. FXIII-B2 stabilizes the (pro)active site-containing FXIII-A subunits. Interestingly, people with genetic FXIII-A deficiency have decreased FXIII-B2, and therapeutic infusion of recombinant FXIII-A2 (rFXIII-A2) increases FXIII-B2, suggesting FXIII-A regulates FXIII-B secretion, production, and/or clearance. We analyzed humans and mice with genetic FXIII-A deficiency and developed a mouse model of rFXIII-A2 infusion to define mechanisms mediating plasma FXIII-B levels. Like humans with FXIII-A deficiency, mice with genetic FXIII-A deficiency had reduced circulating FXIII-B2, and infusion of FXIII-A2 increased FXIII-B2. FXIII-A-deficient mice had normal hepatic function and did not store FXIII-B in liver, indicating FXIII-A does not mediate FXIII-B secretion. Transcriptional analysis and polysome profiling indicated similar F13b levels and ribosome occupancy in FXIII-A-sufficient and -deficient mice and in FXIII-A-deficient mice infused with rFXIII-A2, indicating FXIII-A does not induce de novo FXIII-B synthesis. Unexpectedly, pharmacokinetic/pharmacodynamic modeling of FXIII-B antigen after rFXIII-A2 infusion in humans and mice suggested FXIII-A2 slows FXIII-B2 loss from plasma. Accordingly, comparison of free FXIII-B2 vs FXIII-A2-complexed FXIII-B2 (FXIII-A2B2) infused into mice revealed faster clearance of free FXIII-B2. These data show FXIII-A2 prevents FXIII-B2 loss from circulation and establish the mechanism underlying FXIII-B2 behavior in FXIII-A deficiency and during rFXIII-A2 therapy. Our findings reveal a unique, reciprocal relationship between independently synthesized subunits that mediate an essential hemostatic protein in circulation. This trial was registered at www.ClinicalTrials.com as #NCT00978380.
- Open Access
- 27 December 2023
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 36 (3) , 281-291
Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study
Objectives: This study compared the real-world effectiveness and safety of α4β7-integrin inhibitor vedolizumab and anti-tumor necrosis factor alpha (anti-TNFα) inhibitor infliximab in biologic-naive patients with Crohn’s disease (CD). Methods: EVOLVE was a retrospective, multicenter, medical chart review of biologic-naive adults with inflammatory bowel disease receiving vedolizumab or anti-TNFα treatment as first-line biologics in Canada, Greece, and the USA. Twelve-month outcomes were analyzed in vedolizumab- or infliximab-treated patients with moderate-to-severe CD (and subgroups with complicated and noncomplicated CD) including cumulative rates of clinical response, clinical remission, and mucosal healing, and incidence rates of serious adverse events (SAEs) and serious infections (SIs). Inverse probability weighting (IPW) was used to account for baseline differences between treatment groups. Results: Data were analyzed from 167 patients. In the IPW dataset (99 vedolizumab-treated and 63 infliximab-treated), adjusted 12-month clinical remission rates were 73.1% and 55.2%, respectively (P = 0.31). Overall, effectiveness rates were similar across treatment and complicated/noncomplicated disease subgroups. Adjusted 12-month incidence rates (first occurrence/1000 person-years) of SAEs for vedolizumab vs. infliximab: 43.6 vs. 200.9 [hazard ratio (HR) 0.36 (0.09–1.54)]; SIs: 10.8 vs. 96.0 [HR 0.08 (<0.01–2.64)]. AE incidence was significantly lower in vedolizumab- vs. infliximab-treated patients for complicated [131.6 vs. 732.2; HR 0.19 (0.05–0.65)] and noncomplicated [276.3 vs. 494.8; HR 0.59 (0.35–0.99)] disease subgroups. Conclusion: These real-world data on first-line biologics show no differences in 12-month effectiveness outcomes for vedolizumab- vs. infliximab-treated biologic-naive patients with CD. Vedolizumab may have a more favorable safety profile vs. infliximab in patients with complicated and noncomplicated disease.
- 27 December 2023
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 36 (3) , 281-291
Open AccessEffectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study
Objectives: This study compared the real-world effectiveness and safety of α4β7-integrin inhibitor vedolizumab and anti-tumor necrosis factor alpha (anti-TNFα) inhibitor infliximab in biologic-naive patients with Crohn’s disease (CD). Methods: EVOLVE was a retrospective, multicenter, medical chart review of biologic-naive adults with inflammatory bowel disease receiving vedolizumab or anti-TNFα treatment as first-line biologics in Canada, Greece, and the USA. Twelve-month outcomes were analyzed in vedolizumab- or infliximab-treated patients with moderate-to-severe CD (and subgroups with complicated and noncomplicated CD) including cumulative rates of clinical response, clinical remission, and mucosal healing, and incidence rates of serious adverse events (SAEs) and serious infections (SIs). Inverse probability weighting (IPW) was used to account for baseline differences between treatment groups. Results: Data were analyzed from 167 patients. In the IPW dataset (99 vedolizumab-treated and 63 infliximab-treated), adjusted 12-month clinical remission rates were 73.1% and 55.2%, respectively (P = 0.31). Overall, effectiveness rates were similar across treatment and complicated/noncomplicated disease subgroups. Adjusted 12-month incidence rates (first occurrence/1000 person-years) of SAEs for vedolizumab vs. infliximab: 43.6 vs. 200.9 [hazard ratio (HR) 0.36 (0.09–1.54)]; SIs: 10.8 vs. 96.0 [HR 0.08 (<0.01–2.64)]. AE incidence was significantly lower in vedolizumab- vs. infliximab-treated patients for complicated [131.6 vs. 732.2; HR 0.19 (0.05–0.65)] and noncomplicated [276.3 vs. 494.8; HR 0.59 (0.35–0.99)] disease subgroups. Conclusion: These real-world data on first-line biologics show no differences in 12-month effectiveness outcomes for vedolizumab- vs. infliximab-treated biologic-naive patients with CD. Vedolizumab may have a more favorable safety profile vs. infliximab in patients with complicated and noncomplicated disease.
- Open Access
- 27 November 2023
- Published by Wiley in Molecular Oncology
- Vol. 18 (1) , 113-135
Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. However, the potential contribution of the primary fibrinolytic protease plasminogen to PDAC disease progression has remained largely undefined. Mice bearing C57Bl/6‐derived KPC (KRasG12D, TRP53R172H) tumors displayed evidence of plasmin activity in the form of high plasmin–antiplasmin complexes and high plasmin generation potential relative to mice without tumors. Notably, plasminogen‐deficient mice (Plg‐) had significantly diminished KPC tumor growth in subcutaneous and orthotopic implantation models. Moreover, the metastatic potential of KPC cells was significantly diminished in Plg‐ mice, which was linked to reduced early adhesion and/or survival of KPC tumor cells. The reduction in primary orthotopic KPC tumor growth in Plg‐ mice was associated with increased apoptosis, reduced accumulation of pro‐tumor immune cells, and increased local proinflammatory cytokine production. Elimination of fibrin(ogen), the primary proteolytic target of plasmin, did not alter KPC primary tumor growth and resulted in only a modest reduction in metastatic potential. In contrast, deficiencies in the plasminogen receptors Plg‐RKT or S100A10 in tumor cells significantly reduced tumor growth. Plg‐RKT reduction in tumor cells, but not reduced S100A10, suppressed metastatic potential in a manner that mimicked plasminogen deficiency. Finally, tumor growth was also reduced in NSG mice subcutaneously or orthotopically implanted with patient‐derived PDAC tumor cells in which circulating plasminogen was pharmacologically reduced. Collectively, these studies suggest that plasminogen promotes PDAC tumor growth and metastatic potential, in part through engaging plasminogen receptors on tumor cells.
- 27 November 2023
- Published by Wiley in Molecular Oncology
- Vol. 18 (1) , 113-135
Open AccessPlasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. However, the potential contribution of the primary fibrinolytic protease plasminogen to PDAC disease progression has remained largely undefined. Mice bearing C57Bl/6‐derived KPC (KRasG12D, TRP53R172H) tumors displayed evidence of plasmin activity in the form of high plasmin–antiplasmin complexes and high plasmin generation potential relative to mice without tumors. Notably, plasminogen‐deficient mice (Plg‐) had significantly diminished KPC tumor growth in subcutaneous and orthotopic implantation models. Moreover, the metastatic potential of KPC cells was significantly diminished in Plg‐ mice, which was linked to reduced early adhesion and/or survival of KPC tumor cells. The reduction in primary orthotopic KPC tumor growth in Plg‐ mice was associated with increased apoptosis, reduced accumulation of pro‐tumor immune cells, and increased local proinflammatory cytokine production. Elimination of fibrin(ogen), the primary proteolytic target of plasmin, did not alter KPC primary tumor growth and resulted in only a modest reduction in metastatic potential. In contrast, deficiencies in the plasminogen receptors Plg‐RKT or S100A10 in tumor cells significantly reduced tumor growth. Plg‐RKT reduction in tumor cells, but not reduced S100A10, suppressed metastatic potential in a manner that mimicked plasminogen deficiency. Finally, tumor growth was also reduced in NSG mice subcutaneously or orthotopically implanted with patient‐derived PDAC tumor cells in which circulating plasminogen was pharmacologically reduced. Collectively, these studies suggest that plasminogen promotes PDAC tumor growth and metastatic potential, in part through engaging plasminogen receptors on tumor cells.
- Open Access
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S524-S525
P632 Vedolizumab dose escalation in patients with inflammatory bowel disease experiencing loss of response: A systematic review and meta-analysis of real-world evidence
Moderately to severely active inflammatory bowel disease (IBD), featured as Crohn’s disease (CD) and ulcerative colitis (UC) collectively, is commonly treated with biologic therapies. A proportion of patients experience loss of response (LOR) over time. The approved dose of vedolizumab (VDZ), 300 mg every 8-week (Q8W), is known to be safe and effective in the treatment of UC and CD. In an open-label long-term safety study (GEMINI LTS), patients who experienced LOR during maintenance benefitted from dose escalation to an every 4-week (Q4W) regimen. Clinical response and remission were regained in 41% and 28% respectively in UC patients (N=32) and 47% and 32% respectively in CD patients (N=57) through 52 weeks of escalated dosing. The aim of this study was to conduct a meta-analysis of existing real-world evidences to evaluate the effectiveness of VDZ dose escalation to Q4W in IBD patients experiencing LOR to Q8W dosing. A systematic literature review was performed using PubMed and Embase databases for articles and conference abstracts from January 2014 through January 2019 for real-world studies reporting clinical outcomes to VDZ dose-escalation among adult patients with UC or CD. Relevant congresses were also screened for accepted abstracts through June 2019. Summary estimates for the proportion of regained response and remission were synthesised under a random effect model (given considerable heterogeneity as measured by I2 statistic) using the DerSimonian-Laird approach. The search yielded a total of 842 citations from the databases and 12 citations from hand searching. Of these, 5 full-text articles and 1 abstract were included in the meta-analysis. The 6 study cohorts included a total of 297 patients with IBD. The random-effects pooled regained response rate from the 6 studies was 56.5% (95% confidence interval [CI], 44.9%–67.5%) within 52 weeks (figure). Subgroup analysis showed a regained response rate of 62.7% (95% CI,52.8%–71.6%) when measured within 30 weeks vs. 50.2% (95% CI, 38.3%–62.2%) when measured after 30 weeks. Of the 6 studies, 2 reported remission rates that were included in the pooled analysis among 203 patients experiencing LOR. The random-effects pooled estimate of recaptured remission was 42.4% (95% CI, 25.1%–61.8%) within 52 weeks. More than half of IBD patients who experienced LOR during maintenance phase after initial response to VDZ Q8W dosing regained response on the escalated Q4W regimen within 52 weeks. These findings and the data from the open-label clinical trial support the benefits of VDZ dose escalation among patients experiencing LOR to Q8W dosing.
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S524-S525
Open AccessP632 Vedolizumab dose escalation in patients with inflammatory bowel disease experiencing loss of response: A systematic review and meta-analysis of real-world evidence
Moderately to severely active inflammatory bowel disease (IBD), featured as Crohn’s disease (CD) and ulcerative colitis (UC) collectively, is commonly treated with biologic therapies. A proportion of patients experience loss of response (LOR) over time. The approved dose of vedolizumab (VDZ), 300 mg every 8-week (Q8W), is known to be safe and effective in the treatment of UC and CD. In an open-label long-term safety study (GEMINI LTS), patients who experienced LOR during maintenance benefitted from dose escalation to an every 4-week (Q4W) regimen. Clinical response and remission were regained in 41% and 28% respectively in UC patients (N=32) and 47% and 32% respectively in CD patients (N=57) through 52 weeks of escalated dosing. The aim of this study was to conduct a meta-analysis of existing real-world evidences to evaluate the effectiveness of VDZ dose escalation to Q4W in IBD patients experiencing LOR to Q8W dosing. A systematic literature review was performed using PubMed and Embase databases for articles and conference abstracts from January 2014 through January 2019 for real-world studies reporting clinical outcomes to VDZ dose-escalation among adult patients with UC or CD. Relevant congresses were also screened for accepted abstracts through June 2019. Summary estimates for the proportion of regained response and remission were synthesised under a random effect model (given considerable heterogeneity as measured by I2 statistic) using the DerSimonian-Laird approach. The search yielded a total of 842 citations from the databases and 12 citations from hand searching. Of these, 5 full-text articles and 1 abstract were included in the meta-analysis. The 6 study cohorts included a total of 297 patients with IBD. The random-effects pooled regained response rate from the 6 studies was 56.5% (95% confidence interval [CI], 44.9%–67.5%) within 52 weeks (figure). Subgroup analysis showed a regained response rate of 62.7% (95% CI,52.8%–71.6%) when measured within 30 weeks vs. 50.2% (95% CI, 38.3%–62.2%) when measured after 30 weeks. Of the 6 studies, 2 reported remission rates that were included in the pooled analysis among 203 patients experiencing LOR. The random-effects pooled estimate of recaptured remission was 42.4% (95% CI, 25.1%–61.8%) within 52 weeks. More than half of IBD patients who experienced LOR during maintenance phase after initial response to VDZ Q8W dosing regained response on the escalated Q4W regimen within 52 weeks. These findings and the data from the open-label clinical trial support the benefits of VDZ dose escalation among patients experiencing LOR to Q8W dosing.
- Open Access
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S381-S382
P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
There is little long-term research (≥12 months) in ulcerative colitis (UC) and Crohn’s disease (CD) patients investigating the impact on clinical effectiveness of combined (combo) therapy of vedolizumab (VDZ) plus immunomodulators/immunosuppressants (IMMs) compared with VDZ monotherapy. Research suggests the use of concomitant aminosalicylates [5-ASAs] in UC may not bolster effectiveness. Finally, it is unclear if the safety profile differs between VDZ monotherapy and combo therapy. This study described clinical effectiveness and safety outcomes in patients with UC or CD treated with first-line biologic VDZ as monotherapy or combo therapy with IMMs or 5-ASAs (UC only). This was a real-world, multi-country (Canada, Greece and the USA), retrospective chart review study of biologic-naïve UC and CD patients (≥18 years old) treated with VDZ (initiated Tx May 2014–March 2018). Data were collected from Tx initiation to the earliest of death and chart abstraction date. Cumulative rates of clinical effectiveness outcomes over 24 months (Tx persistence, clinical response and clinical remission) were estimated using the Kaplan-Meier method with unadjusted comparisons conducted using the log-rank test. Clinical response and remission were assessed from standard disease measures reported in medical records. Analyses of unadjusted incidence rates (per 100 person-years [PYs]) of disease exacerbations, disease-related surgeries, serious adverse events (SAEs) and serious infections (SIs) were performed. For these analyses in monotherapy vs. VDZ+IMMs, UC and CD patients were combined due to restrictions of sample size and a number of events. This analysis included 318 patients treated with VDZ (monotherapy: UC = 53, CD = 108; VDZ+IMMs: UC = 22, CD = 24; VDZ+5-ASAs: UC = 111). There were no observed differences in age, sex or disease duration between patients on monotherapy vs. VDZ+IMMs or vs. VDZ+5-ASAs. Data trends in effectiveness outcomes were similar in monotherapy vs. VDZ+IMMs over 24 months (Figure 1). Tx persistence (monotherapy: 71.6%; VDZ+5-ASAs: 82.7%; p = 0.40), clinical remission (monotherapy: 54.3%; VDZ+5-ASAs: 87.7%; p = 0.37) and clinical response (monotherapy: 81.7%; VDZ+5-ASAs: 92.2%; p = 0.54) were also similar between monotherapy and VDZ+5-ASAs over 24 months. Safety outcomes were similar between groups (Figure 2). Though sample sizes were small, the unadjusted trends in the results of this long-term real-world study suggest that biologic-naïve UC or CD patients treated with VDZ alone may have similar clinical effectiveness outcomes to patients receiving VDZ+IMMs. Trends in data also suggest that in patients with UC, VDZ+5-ASAs may not be more effective than VDZ alone.
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S381-S382
Open AccessP419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
There is little long-term research (≥12 months) in ulcerative colitis (UC) and Crohn’s disease (CD) patients investigating the impact on clinical effectiveness of combined (combo) therapy of vedolizumab (VDZ) plus immunomodulators/immunosuppressants (IMMs) compared with VDZ monotherapy. Research suggests the use of concomitant aminosalicylates [5-ASAs] in UC may not bolster effectiveness. Finally, it is unclear if the safety profile differs between VDZ monotherapy and combo therapy. This study described clinical effectiveness and safety outcomes in patients with UC or CD treated with first-line biologic VDZ as monotherapy or combo therapy with IMMs or 5-ASAs (UC only). This was a real-world, multi-country (Canada, Greece and the USA), retrospective chart review study of biologic-naïve UC and CD patients (≥18 years old) treated with VDZ (initiated Tx May 2014–March 2018). Data were collected from Tx initiation to the earliest of death and chart abstraction date. Cumulative rates of clinical effectiveness outcomes over 24 months (Tx persistence, clinical response and clinical remission) were estimated using the Kaplan-Meier method with unadjusted comparisons conducted using the log-rank test. Clinical response and remission were assessed from standard disease measures reported in medical records. Analyses of unadjusted incidence rates (per 100 person-years [PYs]) of disease exacerbations, disease-related surgeries, serious adverse events (SAEs) and serious infections (SIs) were performed. For these analyses in monotherapy vs. VDZ+IMMs, UC and CD patients were combined due to restrictions of sample size and a number of events. This analysis included 318 patients treated with VDZ (monotherapy: UC = 53, CD = 108; VDZ+IMMs: UC = 22, CD = 24; VDZ+5-ASAs: UC = 111). There were no observed differences in age, sex or disease duration between patients on monotherapy vs. VDZ+IMMs or vs. VDZ+5-ASAs. Data trends in effectiveness outcomes were similar in monotherapy vs. VDZ+IMMs over 24 months (Figure 1). Tx persistence (monotherapy: 71.6%; VDZ+5-ASAs: 82.7%; p = 0.40), clinical remission (monotherapy: 54.3%; VDZ+5-ASAs: 87.7%; p = 0.37) and clinical response (monotherapy: 81.7%; VDZ+5-ASAs: 92.2%; p = 0.54) were also similar between monotherapy and VDZ+5-ASAs over 24 months. Safety outcomes were similar between groups (Figure 2). Though sample sizes were small, the unadjusted trends in the results of this long-term real-world study suggest that biologic-naïve UC or CD patients treated with VDZ alone may have similar clinical effectiveness outcomes to patients receiving VDZ+IMMs. Trends in data also suggest that in patients with UC, VDZ+5-ASAs may not be more effective than VDZ alone.
- Open Access
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S019
OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for ulcerative colitis (UC). Using a multicentre, US-based consortium of UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior UC-related hospitalisation within the previous year, disease extent, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the physician global assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of UC-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (Mayo endoscopic subscore of 0 or 1). Hazard ratios (HRs) and 95% confidence intervals (CIs) are reported for VDZ compared with TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.73). Of 646 UC patients, 334 were included after matching (n = 167 VDZ,; 49% male; median age 36 years). After adjusting for concomitant steroid use, concomitant immunomodulator (azathioprine, 6-mercaptopurine, methotrexate) use, and number of prior TNF-antagonists used, VDZ-treated patients had statistically significant higher 12-month cumulative rates of clinical remission (54% vs. 37%; HR 1.54, 95% CI 1.08–2.18) and endoscopic healing (50% vs. 42%, HR 1.73, 95% CI 1.10–2.73). Cumulative 12-month rates for steroid-free remission were numerically higher for VDZ-treated patients, but not statistically significant (49% vs. 38%; HR 1.43, 95% CI 0.79–2.60), These findings were consistent when stratified by disease extent and prior TNF-antagonist exposure. After accounting for measurable disease and patient-specific characteristics that may impact biologic effectiveness, we observed that VDZ-treated UC patients had significantly higher 12-month cumulative rates of clinical remission and endoscopic healing, and numerically higher steroid-free remission rates, when compared with TNF-antagonist–treated patients. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals U.S.A., Inc.
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S019
Open AccessOP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for ulcerative colitis (UC). Using a multicentre, US-based consortium of UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior UC-related hospitalisation within the previous year, disease extent, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the physician global assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of UC-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (Mayo endoscopic subscore of 0 or 1). Hazard ratios (HRs) and 95% confidence intervals (CIs) are reported for VDZ compared with TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.73). Of 646 UC patients, 334 were included after matching (n = 167 VDZ,; 49% male; median age 36 years). After adjusting for concomitant steroid use, concomitant immunomodulator (azathioprine, 6-mercaptopurine, methotrexate) use, and number of prior TNF-antagonists used, VDZ-treated patients had statistically significant higher 12-month cumulative rates of clinical remission (54% vs. 37%; HR 1.54, 95% CI 1.08–2.18) and endoscopic healing (50% vs. 42%, HR 1.73, 95% CI 1.10–2.73). Cumulative 12-month rates for steroid-free remission were numerically higher for VDZ-treated patients, but not statistically significant (49% vs. 38%; HR 1.43, 95% CI 0.79–2.60), These findings were consistent when stratified by disease extent and prior TNF-antagonist exposure. After accounting for measurable disease and patient-specific characteristics that may impact biologic effectiveness, we observed that VDZ-treated UC patients had significantly higher 12-month cumulative rates of clinical remission and endoscopic healing, and numerically higher steroid-free remission rates, when compared with TNF-antagonist–treated patients. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals U.S.A., Inc.
- Open Access
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S018
OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for Crohn’s disease (CD). Using a multicentre, US-based consortium of CD patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior CD-related hospitalisation within the previous year, stricturing or penetrating disease complication history, prior bowel surgery, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the Physician Global Assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of CD-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (absence of ulcers or erosions). Hazard ratios (HR) and 95% confidence intervals (CI) are reported for VDZ vs. TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.80). Of 1122 CD patients, 538 were included after matching (n = 269 VDZ; 44% male; median age 35 years). After adjusting for concomitant steroid or immunomodulator use, disease location (isolated small bowel, ileocolonic, isolated colonic), and number of prior TNF-antagonists used, VDZ-treated patients had numerically, but not statistically significant higher 12-month cumulative rates for clinical remission (38% vs. 34%; HR 1.27, 95% CI 0.91–1.78) and steroid-free remission (26% vs. 18%; HR 1.75, 95% CI 0.90–3.43). VDZ-treated patients had significant higher 12-month cumulative rates for endoscopic healing (50% vs. 41%; HR 1.67, 95% CI 1.13–2.47). Among patients with colonic involvement, VDZ-treated patients had significantly higher rates of clinical remission, steroid-free remission, and endoscopic healing (Table 1). Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. After accounting for measurable disease- and patient-specific characteristics that may affect biological effectiveness, VDZ-treated CD patients had numerically higher 12-month cumulative rates of clinical remission, steroid-free remission, and endoscopic healing than TNF-antagonist-treated patients. CD patients with colonic involvement were significantly more likely to respond to VDZ than to TNF-antagonist therapy. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals.
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S018
Open AccessOP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for Crohn’s disease (CD). Using a multicentre, US-based consortium of CD patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior CD-related hospitalisation within the previous year, stricturing or penetrating disease complication history, prior bowel surgery, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the Physician Global Assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of CD-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (absence of ulcers or erosions). Hazard ratios (HR) and 95% confidence intervals (CI) are reported for VDZ vs. TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.80). Of 1122 CD patients, 538 were included after matching (n = 269 VDZ; 44% male; median age 35 years). After adjusting for concomitant steroid or immunomodulator use, disease location (isolated small bowel, ileocolonic, isolated colonic), and number of prior TNF-antagonists used, VDZ-treated patients had numerically, but not statistically significant higher 12-month cumulative rates for clinical remission (38% vs. 34%; HR 1.27, 95% CI 0.91–1.78) and steroid-free remission (26% vs. 18%; HR 1.75, 95% CI 0.90–3.43). VDZ-treated patients had significant higher 12-month cumulative rates for endoscopic healing (50% vs. 41%; HR 1.67, 95% CI 1.13–2.47). Among patients with colonic involvement, VDZ-treated patients had significantly higher rates of clinical remission, steroid-free remission, and endoscopic healing (Table 1). Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. After accounting for measurable disease- and patient-specific characteristics that may affect biological effectiveness, VDZ-treated CD patients had numerically higher 12-month cumulative rates of clinical remission, steroid-free remission, and endoscopic healing than TNF-antagonist-treated patients. CD patients with colonic involvement were significantly more likely to respond to VDZ than to TNF-antagonist therapy. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals.